Abstract:Background Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype. Methods Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regression was used to identify individual biomarkers associated with 1-year ILD progression, defined as death, lung transplant, or 10% or greater relative forced vital capacity (FVC) decline. A proteomic signature of progressive fibrosing ILD was then derived with use of machine learning in the University of California cohort and validated in the University of Texas cohort. Findings The discovery cohort comprised 385 patients (mean age 63.6 years, 59% female) and the validation cohort comprised 204 patients (mean age 60.7 years, 61% female). 31 biomarkers were associated with progressive fibrosing ILD in the discovery cohort, with 17 maintaining an association in the validation cohort. Validated biomarkers showed a consistent association with progressive fibrosing ILD irrespective of ILD clinical diagnosis. A proteomic signature comprising 12 biomarkers was derived by machine learning and validated in the University of Texas cohort, in which it had a sensitivity of 0.90 and corresponding negative predictive value of 0.91, suggesting that approximately 10% of patients with a low-risk proteomic signature would experience ILD progression in the year after blood draw. Those with a low-risk proteomic signature experienced an FVC change of +85.7 mL (95% CI 6.9 to 164.4) and those with a high-risk signature experienced an FVC change of -227.1 mL (-286.7 to -167.5). A theoretical clinical trial restricted to patients with a high-risk proteomic signature would require 80% fewer patients than one designed without regard to proteomic signature. Interpretation 17 plasma biomarkers of progressive fibrosing ILD were identified and showed consistent associations across ILD subtypes. A proteomic signature of progressive fibrosing ILD could enrich clinical trial cohorts and avoid the need for antecedent progression when defining progressive fibrosing ILD for clinical trial enrolment. Copyright (C) 2022 Elsevier Ltd. All rights reserved.

Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease

Predicting progressive phenotype in patients with fibrotic interstitial lung disease

Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease

The dawn of precision medicine in fibrotic interstitial lung disease

Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

Proteomic Biomarkers of Progressive Fibrosing Interstitial Lung Disease: a Multicentre Cohort Analysis.

Progression of fibrosing interstitial lung disease

Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry

A MICRO CONTACT LENS ELECTRODE *

Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions

Prospects for Treatment of Idiopathic Pulmonary Fibrosis

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

The evolving pharmacotherapy of pulmonary fibrosis

Evidence from recent clinical trials in fibrotic interstitial lung diseases

Molecular Endotyping of Pulmonary Fibrosis

The human small glutamine-rich TPR-containing protein is required for progress through cell division.

Current Challenges and Novel Therapeutic Perspectives

Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression

Highlights on Future Treatments of IPF: Clues and Pitfalls

Genetic Analysis of the Touch Response in Zebrafish (Danio rerio).